Company is solid with revenue above 6-8m and excellent pipeline with clear breakthrough!

Micro float (~600K), great company with increase in YoY revenue, and high analyst price targets.

$HTGM shows quite a strong growth in Revenue.

$HTGM money making company already bringing in the revenue

$HTGM Yep 6m revenue, 12m cash, 3m cap! superbullish!

Two other drugs, each growing revenue steadily.

That said, I fully expect continuing script and revenue growth, upcoming cashflow breakeven and some nice juicy licensing deals to resolve that in the months ahead.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

There is so much good news here, growing revenue, a stable base, conservative management, and connections to big pharma.

$BCRX shows a strong growth in Revenue.

$BCRX shows a strong growth in Revenue.

$BCRX shows a strong growth in Revenue.

We have a revenue generating drug thats just achieved 105% YoY growth.

Company had revenue and cash both in the current market much better than most bios out there.

but interesting From an Orladeyo standpoint, they are setting themselves up for a revenue beat next year.

Streamlined presentation (even nicer graphics), focus on revenue through 2039 with Orla, moving on from 9930, simple plan (we’ve been there before and lessons were learned) for 10013.

$BCRX so they hit their Q4 numbers, had stellar phase IA results and guided for a 70Mil increase in revenue in 202e.

A near-term positive catalyst could be a surprise revenue beat.